Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
Received 20 November 2018
Accepted for publication 29 January 2019
Published 13 September 2019 Volume 2019:15 Pages 2655—2661
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Roger Pinder
Reiji Yoshimura,1,* Taro Kishi,2,* Nakao Iwata2
1Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 8078555, Japan; 2Department of Psychiatry, Fujita Medical University, Toyoake Aichi 4701192, Japan
*These authors contributed equally to this work
Correspondence: Reiji Yoshimura
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu Fukuoka 8078555, Japan
Objective: IL-6 and catecholamines play roles in the pathophysiology of major depressive disorder (MDD).
Aim: The present study investigated associations between plasma IL-6 and plasma catecholamine metabolites in patients with MDD.
Participants and methods: A total of 148 patients (male/female 65/83, age 49.5±12.1 years) who met the criteria for MDD based on the Diagnostic and Statistical Manual of Mental Disorders IV and 40 participants as healthy controls (HC; male/female 23/17, age 44.0±10.5 years) were enrolled in the present study. Plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA) were analyzed using high-performance liquid chromatography, and plasma IL-6 levels were measured using ELISA.
Results: No correlations were observed among plasma IL-6 levels, MHPG levels, and HVA levels in patients with MDD. Plasma IL-6 levels in patients with MDD were significantly higher than in the HC. A positive correlation was found between plasma IL-6 levels and Hamilton Rating Scale for Depression-17 scores.
Conclusion: No correlations existed between plasma IL-6 levels and plasma catecholamine metabolite levels in patients with MDD, and the severity of depressive state was related to plasma IL-6 levels in MDD.
Keywords: IL-6, 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, major depressive disorder, Hamilton Rating Scale for Depression
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]